Salute e Benessere
Implantica presents the third quarter 2024 on November 15 at 15:00 CEST
If you wish to participate via webcast, please use the following link:
If you wish to participate via teleconference, please register on the link below. After registration, you will be provided the phone number and a conference ID to access the conference.
Speakers:
Nicole Pehrsson , Investor Relations
Telephone (CH): +41 (0)79 335 09 49
nicole.pehrsson@implantica.com
Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm .
The company's Certified Adviser is FNCA Sweden AB, info@fnca.se
Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content: https://www.prnewswire.co.uk/news-releases/implantica-presents-the-third-quarter-2024-on-november-15-at-1500-cest-302299862.html